Neumora

peterschreiber.media Mizuho started coverage of Neumora Therapeutics (NASDAQ:NMRA) with an outperform rating, stating it sees 50%+ upside to the stock if the company reports positive Phase 3 data for its lead drug navacaprant in the treatment of major depressive disorder. The investment bank noted the Phase 3 data is expectedContinue Reading